Harbour Investments’s 10x Genomics TXG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$11K Sell
287
-35
-11% -$917 ﹤0.01% 3306
2026
Q1
$6.84K Buy
322
+95
+42% +$1.9K ﹤0.01% 3451
2025
Q4
$3.7K Hold
227
– – ﹤0.01% 3128
2025
Q3
$2.65K Hold
227
– – ﹤0.01% 3198
2025
Q2
$2.63K Hold
227
– – ﹤0.01% 3059
2025
Q1
$1.98K Buy
227
+38
+20% +$479 ﹤0.01% 3086
2024
Q4
$2.71K Buy
189
+120
+174% +$1.89K ﹤0.01% 2929
2024
Q3
$1.56K Buy
69
+44
+176% +$910 ﹤0.01% 2991
2024
Q2
$486 Hold
25
– – ﹤0.01% 3089
2024
Q1
$938 Hold
25
– – ﹤0.01% 2935
2023
Q4
$1.4K Hold
25
– – ﹤0.01% 2760
2023
Q3
$1.03K Sell
25
-90
-78% -$4.68K ﹤0.01% 2694
2023
Q2
$6.42K Hold
115
– – ﹤0.01% 2200
2023
Q1
$6.42K Buy
115
+90
+360% +$4.2K ﹤0.01% 2195
2022
Q4
$911 Sell
25
-2
-7% -$65 ﹤0.01% 2703
2022
Q3
$1K Hold
27
– – ﹤0.01% 2665
2022
Q2
$1K Buy
+27
New +$1.4K ﹤0.01% 2665
2021
Q4
$4K Sell
27
-8
-23% -$1.23K ﹤0.01% 2267
2021
Q3
$5K Buy
35
+4
+13% +$687 ﹤0.01% 3025
2021
Q2
$6K Buy
31
+5
+19% +$905 ﹤0.01% 2995
2021
Q1
$5K Buy
+26
New +$4.49K ﹤0.01% 2939

Other funds holding TXG

Harbour Investments's TXG Position: Q2 2026 in Review

Harbour Investments reduced its 10x Genomics (TXG) stake by 11% in Q2 2026, selling an estimated $917 and leaving 287 shares worth $11K. The position accounts for ﹤0.01% of the portfolio, ranked #3306.

Harbour Investments first reported a position in TXG in Q1 2021 and has held it in 21 quarters since. 393 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Harbour Investments held 287 shares of 10x Genomics worth $11K as of Q2 2026.
  • Harbour Investments sold 35 10x Genomics shares in Q2 2026, an estimated $917.
  • 10x Genomics made up ﹤0.01% of Harbour Investments's portfolio in Q2 2026, its #3306 holding.
  • Harbour Investments first reported a position in 10x Genomics in Q1 2021 and has held it in 21 quarters since.
  • 393 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Harbour Investments's 13F filing for Q2 2026, filed 12 Aug 2026.